Sex and systemic lupus erythematosus: The role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells

Current Opinion in Rheumatology

Volumn 18, Issue 5, 2006, Pages 456-461

  Grimaldi, Christine M ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

B cell; Estrogen; Prolactin; Systemic lupus erythematosus

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; ESTROGEN; PROLACTIN; SEX HORMONE;

ANTIGEN SPECIFICITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL MATURATION; CELL SURVIVAL; HORMONAL REGULATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; B-LYMPHOCYTES; CELL SURVIVAL; ESTROGENS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, TRANSGENIC; PROLACTIN; SELF TOLERANCE; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 33746864127     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000240354.37927.dd     Document Type: Review

References (61)

1. Whitacre CC, Reingold SC, O'Looney PA, et al. BIOMEDICINE: a gender gap in autoimmunity. Science 1999; 283:1277-1278.
2. Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85:303-306.
3. Meyer O. Making pregnancy safer for patients with lupus. Joint Bone Spine 2004; 71:178-182.
4. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum 1979; 22:1195-1198.
5. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Increased 16 alpha-hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab 1981; 53:174-178.
6. Lahita RG, Bradlow HL, Fishman J, Kunkel HG. Abnormal estrogen and androgen metabolism in the human with systemic lupus erythematosus. Am J Kidney Dis 1982; 2:206-211.
7. Weidler C, Harle P, Schedel J, et al. Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J Rheumatol 2004; 31:489-494.
8. Kanda N, Tsuchida T, Tamaki K. Estrogen enhancement of antidouble-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1999; 42:328-337.
9. Kanda N, Tsuchida T, Tamaki K. Testosterone suppresses anti-DNA antibody production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40:1703-1711.
10. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2550-2558. This was the first relatively large study to examine the safety of oral contraceptives in SLE patients.
11. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus, a randomized trial. Ann Intern Med 2005; 142: 953-962. This describes the first relatively large study to examine the safety of hormone replacement therapy in SLE patients.
12. Roubinian JR, Talal N, Greenspan JS, et al. Effect of castration and sex hormone treatment on survival, antinucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 1978; 147:1568-1583.
13. Roubinian J, Talal N, Siiteri PK, Sadakian JA. Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum 1979; 22:1162-1169.
14. Carlsten H, Holmdahl R, Tarkowski A, Nilsson LA. Oestradiol and testosterone-mediated effects on the immune system in normal and autoimmune mice are genetically linked and inherited as dominant traits. Immunology 1989; 68:209-214.
15. Carlsten H, Tarkowski A, Holmdahl R, Nilsson LA. Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice. Clin Exp Immunol 1990; 80:467-473.
16. Offen D, Spatz L, Escowitz H, et al. Induction of tolerance to an IgG autoantibody. Proc Natl Acad Sci U S A 1992; 89:8332-8336.
17. Bynoe MS, Spatz L, Diamond B. Characterization of anti-DNA B cells that escape negative selection. Eur J Immunol 1999; 29:1304-1313.
18. Spatz L, Saenko V, Iliev A, et al. Light chain usage in antidouble-stranded DNA B cell subsets: role in cell fate determination. J Exp Med 1997; 185:1317-1326.
19. Bynoe MS, Grimaldi CM, Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc Natl Acad Sci USA 2000; 97:2703-2708.
20. Medina KL, Garrett KP, Thompson LF, et al. Identification of very early lymphoid precursors in bone marrow and their regulation by estrogen. Nat Immunol 2001; 2:718-724.
21. Medina KL, Smithson G, Kincade PW. Suppression of B lymphopoiesis during normal pregnancy. J Exp Med 1993; 178:1507-1515.
22. Smithson G, Medina K, Ponting I, Kincade PW. Estrogen suppresses stromal cell-dependent lymphopoiesis in culture. J Immunol 1995; 155:3409-3417.
23. Loder F, Mutschler B, Ray RJ, et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 1999; 190:75-90.
24. Allman D, Lindsley RC, DeMuth W, et al. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001; 167:6834-6840.
25. Grimaldi CM, Michael DJ, Diamond B. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol 2001; 167:1886-1890.
26. Grimaldi CM, Cleary J, Dagtas AS, et al. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002; 109:1625-1633.
27. Grimaldi CM, Jeganathan V, Diamond B. Hormonal regulation of B cell development: 17beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J Immunol 2006; 176:2703-2710. The authors demonstrate that estrogen alters selection of high affinity autoreactive transitional B cells and enhances development into mature B cell subsets. Also discusses significance of low affinity autoantibodies.
28. Peeva E, Venkatesh J, Diamond B. Tamoxifen blocks estrogen-induced B cell maturation but not survival. J Immunol 2005; 175:1415-1423. Studies showed that some of the effects of estrogen on the regulation of autoreactive B cells can be blocked by estrogen receptor modulation.
29. Wu WM, Lin BF, Su YC, et al. Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. Scand J Immunol 2000; 52:393-400.
30. Wu WM, Suen JL, Lin BF, Chiang BL. Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice. Immunology 2000; 100:110-118.
31. Werwitzke S, Trick D, Kamino K, et al. Inhibition of lupus disease by antidouble-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse. Arthritis Rheum 2005; 52:3629-3638. This interesting study provided evidence that low affinity anti-DNA antibodies protect against the kidney damage mediated by high affinity anti-DNA antibodies and may be useful for the treatment of SLE.
32. Kim SJ, Gershov D, Ma X, et al. I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med 2002; 196:655-665.
33. Venkatesh J, Peeva E, Xu X, Diamond B. Cutting edge: hormonal milieu, not antigenic specificity, determines the mature phenotype of autoreactive B cells. J Immunol 2006; 176:3311-3314. The authors demonstrate that DNA-reactive B cells bearing the same heavy and light chain combinations can become either marginal zone or follicular B cells depending on type of hormone exposure. They also show that BAFF levels may be increased by estrogen, but not by prolactin and that estrogen can reduce the strength of the BCR signal.
34. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20:441-453.
35. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20:785-798.
36. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55:3902-3907.
37. Strasser A, Whittingham S, Vaux DL, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A 1991; 88:8661-8665.
38. Hartley SB, Cooke MP, Fulcher DA, et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell 1993; 72:325-335.
39. Goodnow CC, Crosbie J, Adelstein S, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 1988; 334:676-682.
40. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989; 337:562-566.
41. Grimaldi CM, Hicks R, Diamond B. B cell selection and susceptibility to autoimmunity. J Immunol 2005; 174:1775-1781.
42. White R, Lees JA, Needham M, et al. Structural organization and expression of the mouse estrogen receptor. Mol Endocrinol 1987; 1:735-744.
43. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82:4258-4265.
44. Yurino H, Ishikawa S, Sato T, et al. Endocrine disruptors (environmental estrogens) enhance autoantibody production by B1 cells. Toxicol Sci 2004; 81:139-147.
45. Suenaga R, Evans MJ, Mitamura K, et al. Peripheral blood T cells and monocytes and B cell lines derived from patients with lupus express estrogen receptor transcripts similar to those of normal cells. J Rheumatol 1998; 25:1305-1312.
46. Shim GJ, Gherman D, Kim HJ, et al. Differential expression of oestrogen receptors in human secondary lymphoid tissues. J Pathol 2006; 208: 408-414. Results suggest that only ERβ is expressed in human B cells; other data, however, suggest both estrogen receptors are expressed in B cells.
47. Johansson M, Arlestig L, Moller B, et al. Oestrogen receptor a gene polymorphisms in systemic lupus erythematosus. Ann Rheum Dis 2005; 64:1611-1617. The authors provide intriguing evidence that genetic alteration in ERα associates with SLE.
48. Kassi E, Vlachoyiannopoulos PG, Kominakis A, et al. Estrogen receptor alpha gene polymorphism and systemic lupus erythematosus: a possible risk? Lupus 2005; 14:391-398. The authors provide intriguing evidence that genetic alterations in ERα associate with SLE.
49. Shim GJ, Kis LL, Warner M, Gustafsson JA. Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc Natl Acad Sci U S A 2004; 101:1720-1724.
50. Allen SH, Sharp GC, Wang G, et al. Prolactin levels and antinuclear antibody profiles in women tested for connective tissue disease. Lupus 1996; 5:30-37.
51. Neidhart M. Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 1996; 23:476-481.
52. McMurray R, Keisler D, Kanuckel K, et al. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 1991; 147:3780-3787.
53. Walker SE, McMurray RW, Houri JM, et al. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Ann N Y Acad Sci 1998; 840:762-772.
54. Walker SE, Reddy GH, Miller D, et al. Treatment of active SLE with the prolactin lowering drug, bromocriptine: comparison with hydroxychloroquine in a nonrandomized blinded one-year study. Arthritis Rheum 1999; 42:S282.
55. McMurray RW, Weidensaul D, Allen SH, Walker SE. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 1995; 22:2084-2091.
56. Neidhart M. Bromocriptine has little direct effect on murine lymphocytes, the immunomodulatory effect being mediated by the suppression of prolactin secretion. Biomed Pharmacother 1997; 51:118-125.
57. Elbourne KB, Keisler D, McMurray RW. Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus. Lupus 1998; 7:420-427.
58. Peeva E, Michael D, Cleary J, et al. Prolactin modulates the naive B cell repertoire. J Clin Invest 2003; 111:275-283.
59. Gagnerault MC, Touraine P, Savino W, et al. Expression of prolactin receptors in murine lymphoid cells in normal and autoimmune situations. J Immunol 1993; 150:5673-5681.
60. Goffin V, Binart N, Touraine P, Kelly PA. Prolactin: the new biology of an old hormone. Annu Rev Physiol 2002; 64:47-67.
61. Peeva E, Grimaldi C, Spatz L, Diamond B. Bromocriptine restores tolerance in estrogen-treated mice. J Clin Invest 2000; 106:1373-1379.